Return to Angiogenesis Alert Section
New angiogenesis study findings recently were published by A.D. Hauer and co-researchers
November 26th, 2007
2007 NOV 26 -- According to a study from Netherlands, "Objective-Vascular endothelial growth factor receptor 2 ( VEGFR2)-overexpressing cells may form an interesting target for the treatment of atherosclerosis because of their involvement in processes that contribute to this disease, such as angiogenesis. Methods and Results-We vaccinated mice against VEGFR2 by an orally administered DNA vaccine, comprising a plasmid, encoding murine VEGFR2, carried by live attenuated Salmonella typhimurium." "This vaccine induces cellular immunity against cells that overexpress VEGFR2. Vaccination of hypercholesterolemic mice against VEGFR2 resulted in a marked induction of CD8(+) cytotoxic T cells specific for VEGFR2 and led to an inhibition of angiogenesis in a hindlimb ischemia model. Interestingly, VEGFR2 vaccination attenuated the progression of preexisting advanced atherosclerotic lesions in the brachiocephalic artery of apoE(-/)-mice. Furthermore, VEGFR2 vaccination strongly reduced the initiation of collar-induced atherosclerosis in the carotid arteries of LDLr-/-mice. In addition, denudation of the carotid artery, as a model for postinterventional lesion formation, resulted in delayed endothelial replacement and significantly increased neointima formation on VEGFR2 vaccination," wrote A.D. Hauer and colleagues. The researchers concluded: "Conclusions-These data indicate the prominent role of VEGFR2(+) cells in cardiovascular diseases and show that induction of cellular immunity against atherosclerosis-associated cells by means of DNA vaccination may contribute to the development of novel therapies against atherosclerosis." Hauer and colleagues published the results of their research in Arteriosclerosis Thrombosis and Vascular Biology (Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology, 2007;27(9):2050-2057). For additional information, contact A.D. Hauer, Gorlaeus Laboratories, Division Biopharmaceut, POB 9502, NL-2300 RA Leiden, Netherlands. The publisher of the journal Arteriosclerosis Thrombosis and Vascular Biology can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA. Keywords: Netherlands, Angiogenesis, Oncology, Tumor Vascularization. This article was prepared by Pharma Business Week editors from staff and other reports. Copyright 2007, Pharma Business Week via NewsRx.com.
Return to Angiogenesis Alert Section
|
